TOWA CORPORATION FY2027 Q1 Earnings Report

Financial Highlights

• Net Sales: ¥16.18B
• Operating Income: ¥2.21B
• Net Income: ¥1.66B
• EPS: ¥22.09

Income Statement

Balance Sheet

Profitability Ratios

Year-over-Year Comparison

Share Information

Segment Information

Full Year Forecast

---

AI Financial Analysis

Executive Summary

Verdict: A strong turnaround quarter with sharp top-line recovery and restored profitability, supported by margin expansion and healthy balance-sheet liquidity, albeit with elevated working-capital intensity and refinancing concentration to monitor. Revenue doubled to 161.8bn yen (+100.3% YoY), driving operating income to 22.1bn yen (+480.7% YoY) and net income to 16.6bn yen (+413.8% YoY). Gross profit rose to 54.5bn yen with gross margin at 33.7%, up approximately 703 bps YoY. Operating margin improved from roughly -7.2% to 13.7%, a ~2,089 bps expansion, reflecting strong operating leverage as SG&A ratio fell to 20.0%. Net margin improved from about -6.5% to 10.2%, a ~1,674 bps expansion, aided by lower non-operating drag than the prior year. Ordinary income reached 23.3bn yen (+418.6% YoY), with interest coverage at 30.6x indicating ample capacity to service debt. Semiconductor Equipment remained the core profit engine, contributing 95.7% of revenue and 21.3bn yen of operating income at a 14.1% segment margin. Medical Device delivered 6.8bn yen of sales and 1.32bn yen operating income, with a higher 19.5% margin, providing diversification albeit at a small scale. Liquidity is strong: current ratio at 227% and cash/short-term debt at 1.98x, though 80.7% short-term debt concentration raises refinancing risk if credit conditions tighten. Capital efficiency is still subdued (ROE 2.2% for the quarter; ROIC 2.4%) due to low asset turnover (0.139), suggesting recovery is not yet translating into robust returns on invested capital. Earnings quality warrants monitoring given the very long cash conversion cycle (937 days), high DSO (401 days), and elevated inventory intensity, particularly WIP concentration, which can delay cash realization. Comprehensive income surged to 64.1bn yen, largely from valuation gains in securities and FX translation, improving equity buffers. Guidance appears attainable with Q1 progress broadly in line with 25% seasonality for sales and slightly below for profits but within tolerance. Forward-looking, the company is well-positioned if the semiconductor capex cycle continues to normalize; however, the long working-capital cycle and segment concentration remain key swing factors for free cash flow and volatility. Net of risks, the quarter marks a decisive recovery phase with improved profitability metrics and strong liquidity underpinning the path to the full-year plan.

Profitability Analysis

ROE decomposition (DuPont 3-factor): ROE 2.2% = Net Profit Margin 10.2% × Asset Turnover 0.139 × Financial Leverage 1.54x. The largest improvement YoY is the Net Profit Margin, which rebounded from a negative level last year to 10.2%, followed by Asset Turnover rising from roughly 0.08 to 0.14 as revenue doubled against a modestly larger asset base. The business drivers were a rapid demand recovery in Semiconductor Equipment and strong operating leverage: SG&A grew in absolute terms but the SG&A ratio fell to 20.0%, and gross margin expanded by about 703 bps YoY on better mix and scale benefits. Non-operating drag also eased compared with the prior year’s heavier FX losses, supporting Ordinary income. Sustainability: margin gains are partly cyclical; while cost discipline appears durable, the elevated non-operating volatility (FX) and industry cycle sensitivity suggest some normalization risk in subsequent quarters. Watch for cost reinflation or pricing pressure as order intake mix shifts. A notable caution is that expense growth control must remain tighter than revenue growth; currently SG&A growth lagged revenue growth materially, a positive operating leverage signal that should be monitored for persistence.

Growth Assessment

Top-line growth of +100.3% YoY reflects a robust rebound in core semiconductor equipment demand. Operating income growth of +480.7% YoY indicates substantial operating leverage from higher volumes and an improved mix. Gross margin improved to 33.7%, implying better absorption and potentially favorable product mix. Medical Device growth (+14.5% sales, +29.3% operating income) supports diversified contribution at a small base. Non-operating items were net positive vs prior-year impact, aided by higher dividend/interest income relative to interest expense and lower FX losses. Given the cyclicality of semiconductor capex, sustaining this growth will depend on order momentum and lead-times converting into shipments without further elongation of working capital. The elevated comprehensive income from securities valuation expands capital buffers but is non-cash and market-dependent. Overall growth quality is improving on operating metrics, but conversion to cash must be monitored given the long CCC.

Financial Health

Liquidity is strong: current ratio 227% and quick ratio 208% indicate ample short-term coverage, supported by 297.2bn yen in cash and deposits and 133.0bn yen of investment securities. Leverage is moderate: D/E 0.54x and Debt/Capital 19.8% align with an investment-grade profile; interest coverage at 30.6x reflects comfortable debt serviceability. Refinancing and maturity profile warrant attention: short-term debt ratio is 80.7%, which is high, though cash/short-term debt at 1.98x provides a cushion. Maturity mismatch risk is limited at present as current assets (712.6bn yen) comfortably exceed current liabilities (313.8bn yen), and cash alone exceeds short-term loans. Investment securities increased significantly (+76.1% YoY), bolstering financial flexibility but adding market valuation exposure. Short-term loans increased 30.4% YoY to 150.0bn yen, raising refinancing concentration risk if liquidity conditions tighten.

Notable B/S Changes

Investment Securities: +57.46bn yen (+76.1%) - Larger financial asset base; boosts liquidity and AOCI sensitivity. Short-term Loans: +35.00bn yen (+30.4%) - Higher reliance on short-term funding; elevates refinancing concentration risk.

Cash Flow Quality

Earnings conversion risk is elevated given working-capital intensity: DSO at 401 days, DIO flagged as high, and CCC at 937 days suggest delayed cash realization from revenue. The high WIP share in inventory points to long manufacturing and acceptance cycles typical in capital equipment, which can defer operating cash inflows into later quarters. While cash and securities are sizeable relative to short-term obligations, sustained growth will require disciplined working-capital management to prevent profit-to-cash slippage. No indications of one-time gains distorting operating profit, and extraordinary items are negligible; the primary cash quality watchpoint is the pace of receivable collection and inventory turnover.

Dividend Sustainability

The company guides to DPS of 24.0 yen against forecast EPS of 93.3 yen, implying a payout ratio of approximately 25.7%, well within sustainable levels. Liquidity is strong and leverage is moderate, supporting dividend continuity. Given the long cash conversion cycle, continued dividend sustainability rests on maintaining order-to-cash discipline; however, the low payout provides ample buffer even if cash generation lags accounting profits in intermediate quarters. No buybacks are indicated; thus, focus remains on dividend-only payout.

Risk Assessment

Business risks include Semiconductor cycle sensitivity: demand/orders in core equipment can swing with foundry/OSAT capex shifts, Concentration risk: Semiconductor Equipment accounts for 95.7% of revenue, increasing exposure to a single end-market, Execution risk on long lead-time projects: elevated WIP and long CCC can delay revenue recognition and cash, FX volatility: non-operating FX losses can impact earnings variability.

Financial risks include Refinancing concentration: short-term debt ratio at 80.7% raises rollover risk if markets tighten, Capital efficiency: ROIC at 2.4% indicates underutilized asset base and low asset turnover, Working-capital intensity: DSO 401 days, high DIO, and CCC 937 days constrain cash conversion.

Key concerns include ⚠️ REFINANCING_RISK: Short-term debt ratio 81% suggests reliance on short maturities; while cash/STD is 1.98x and interest coverage 30.6x, a credit squeeze could pressure refinancing costs and liquidity management, ⚠️ CAPITAL_EFFICIENCY: ROIC 2.4% is below a 5% threshold; typical for early upturns in cyclical capital goods, but improvement in asset turnover is needed to lift returns toward cost of capital, ⚠️ HIGH_RECEIVABLE_DAYS: DSO 401 days indicates slow collections, common in project-based equipment but elevated; it heightens working-capital needs and FCF execution risk, ⚠️ HIGH_INVENTORY_DAYS: Inventory days flagged as high point to potential overstock or extended build cycles; risk of obsolescence if demand softens, ⚠️ LONG_CCC: CCC at 937 days is very long for manufacturing; restricts cash generation and raises reliance on external funding for growth, ⚠️ HIGH_WIP_RATIO: WIP at 59.7% of inventory implies long production/acceptance cycles; slippage in project milestones could defer revenue and cash inflows.

Investment Implications

Key takeaways include Sharp profit rebound with operating margin at 13.7% and net margin at 10.2%, Operating leverage visible as SG&A ratio fell to 20.0% amid doubling of sales, Liquidity robust and leverage moderate, but debt maturity skewed short-term, Working-capital velocity is the main governor of FCF; CCC and WIP levels need improvement, Guidance tracking broadly on plan after Q1; profit progress slightly below 25% but within tolerance, Comprehensive income gains enhance equity via securities valuation, providing an additional capital buffer.

Metrics to watch include Order intake and backlog conversion to shipments, DSO, DIO, and CCC trajectory quarter-on-quarter, Segment margins in Semiconductor Equipment versus Medical Device, Short-term debt rollover profile and interest costs, Gross margin stability versus input costs and pricing, ROIC progression as asset turnover normalizes.

Regarding relative positioning, Within Japanese semiconductor capital equipment peers, the company demonstrates a convincing early-cycle earnings recovery with healthy operating leverage and balance-sheet liquidity. However, capital efficiency and cash conversion currently trail best-in-class peers due to elongated receivable and WIP cycles. Successful normalization of working capital and sustained order momentum would narrow this gap.